- The g astrointestinal ( GI ) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group .

- Ultra-long-acting subcutaneous ( SQ ) depot formulation of ASC47 demonstrated a lower rebound effect after treatment discontinuation compared to the semaglutide monotherapy group, supporting the potential use of once-monthly ASC47 as a maintenance therapy.

HONG KONG , Sept. 21, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC47, a muscle-preserving weight loss drug

See Full Page